Monographie - Tacrolimus - Stabilis 4.0

Posledná aktualizácia :
19/11/2024

imunosupresívum

Tacrolimus

Perorálny roztok

Injekcia

Očná instilácia

Stabilita farmaceutických prípravkov

Stabilita v zmesiach

Faktory ovplyvňujúce stabilitu

Kompatibility

Odkazy na literatúru

PDF

Chemický vzorec

Perorálny roztok

Odkazy na literatúru

Perorálny roztok

Odkazy na literatúru : Tacrolimus

	Typ	Publikácia
2436	Časopis	Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789	Časopis	Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL. Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846	Časopis	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
3946	Časopis	Friciu M, Zaraa S, Leclair G. Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177	Časopis	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4673	Časopis	Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V. Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases. Pharmaceutics 2022 ;14,1:118

Mentions Légales